Orphan drug designation for Indivior PLC’s Sublocade (buprenorphine extended-release) was improperly granted 25 years ago under the Orphan Drug Act’s cost recovery provision and should be revoked, the US Food and Drug Administration said in a first-of-its kind decision.
Based on the facts and circumstances at the time buprenorphine first received orphan drug designation for opioid addiction in 1994,...





